S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Save $200 on MarketBeat All Access (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
Save $200 on MarketBeat All Access (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Save $200 on MarketBeat All Access (Ad)
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
North Korea notifies neighboring Japan it plans to launch satellite in coming days
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Save $200 on MarketBeat All Access (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
Save $200 on MarketBeat All Access (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Save $200 on MarketBeat All Access (Ad)
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
North Korea notifies neighboring Japan it plans to launch satellite in coming days
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Save $200 on MarketBeat All Access (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
Save $200 on MarketBeat All Access (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Save $200 on MarketBeat All Access (Ad)
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
North Korea notifies neighboring Japan it plans to launch satellite in coming days
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Save $200 on MarketBeat All Access (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
Save $200 on MarketBeat All Access (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Save $200 on MarketBeat All Access (Ad)
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
North Korea notifies neighboring Japan it plans to launch satellite in coming days
NASDAQ:RXDX

Prometheus Biosciences (RXDX) Stock Forecast, Price & News

$198.60
0.00 (0.00%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$198.51
$198.79
50-Day Range
$106.47
$198.70
52-Week Range
$22.31
$198.99
Volume
1.09 million shs
Average Volume
898,639 shs
Market Capitalization
$9.50 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$153.36

Prometheus Biosciences MarketRank™ Forecast

Analyst Rating
Hold
2.36 Rating Score
Upside/​Downside
22.8% Downside
$153.36 Price Target
Short Interest
Bearish
14.40% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.72mentions of Prometheus Biosciences in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$105.75 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.84) to ($4.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.44 out of 5 stars

Medical Sector

944th out of 1,010 stocks

Pharmaceutical Preparations Industry

471st out of 494 stocks


RXDX stock logo

About Prometheus Biosciences (NASDAQ:RXDX) Stock

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.

Receive RXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prometheus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RXDX Stock News Headlines

Prometheus Biosciences (NASDAQ: RXDX)
Free SMS Trade Alerts. Up to 15 opportunities a day.
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Free SMS Trade Alerts. Up to 15 opportunities a day.
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Prometheus Biosciences (NASDAQ:RXDX) Downgraded by Guggenheim
See More Headlines
Receive RXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prometheus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RXDX Company Calendar

Last Earnings
5/09/2023
Today
5/29/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RXDX
Fax
N/A
Employees
72
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$153.36
High Stock Price Forecast
$200.00
Low Stock Price Forecast
$60.00
Forecasted Upside/Downside
-22.8%
Consensus Rating
Hold
Rating Score (0-4)
2.36
Research Coverage
11 Analysts

Profitability

Net Income
$-141,750,000.00
Net Margins
-3,768.76%
Pretax Margin
-3,768.76%

Debt

Sales & Book Value

Annual Sales
$4.00 million
Book Value
$16.12 per share

Miscellaneous

Free Float
46,187,000
Market Cap
$9.50 billion
Optionable
Not Optionable
Beta
-0.50

Social Links


Key Executives

  • Mr. Mark C. McKenna (Age 42)
    Pres, CEO & Chairman
    Comp: $2.22M
  • Dr. Keith W. Marshall M.B.A. (Age 54)
    MBA, Ph.D., Chief Financial Officer
    Comp: $971.67k
  • Mr. Mark Stenhouse (Age 55)
    Chief Operating Officer
    Comp: $679.71k
  • Dr. Allison Luo M.D. (Age 49)
    Chief Medical Officer
    Comp: $827.97k
  • Dr. Olivier Laurent Ph.D. (Age 50)
    Chief Scientific Officer & Head of R&D
  • Ms. Noel Kurdi
    VP of Investor Relations & Communications
  • Mr. Timothy K. Andrews Esq. (Age 43)
    Gen. Counsel & Sec.
  • Ms. Nori Ebersole (Age 57)
    Chief People Officer
  • Dr. Thierry Dervieux DABCC (Age 54)
    Ph.d., Pharm.d., Chief Devel. Officer of Diagnostics & Medical Laboratory Director
  • Mr. Chris Doughty
    Chief Bus. Officer













RXDX Stock - Frequently Asked Questions

Should I buy or sell Prometheus Biosciences stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prometheus Biosciences in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RXDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RXDX, but not buy additional shares or sell existing shares.
View RXDX analyst ratings
or view top-rated stocks.

What is Prometheus Biosciences' stock price forecast for 2023?

11 brokers have issued 12 month price targets for Prometheus Biosciences' stock. Their RXDX share price forecasts range from $60.00 to $200.00. On average, they predict the company's stock price to reach $153.36 in the next year. This suggests that the stock has a possible downside of 22.8%.
View analysts price targets for RXDX
or view top-rated stocks among Wall Street analysts.

How have RXDX shares performed in 2023?

Prometheus Biosciences' stock was trading at $110.00 on January 1st, 2023. Since then, RXDX stock has increased by 80.5% and is now trading at $198.60.
View the best growth stocks for 2023 here
.

When is Prometheus Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our RXDX earnings forecast
.

How were Prometheus Biosciences' earnings last quarter?

Prometheus Biosciences, Inc. (NASDAQ:RXDX) posted its earnings results on Tuesday, May, 9th. The biopharmaceutical company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.06. The biopharmaceutical company earned $1.11 million during the quarter, compared to analyst estimates of $0.46 million. Prometheus Biosciences had a negative trailing twelve-month return on equity of 33.50% and a negative net margin of 3,768.76%. The firm's revenue was down 71.8% on a year-over-year basis.

What other stocks do shareholders of Prometheus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prometheus Biosciences investors own include Cronos Group (CRON), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Freeport-McMoRan (FCX), (KITE) (KITE), La Jolla Pharmaceutical (LJPC), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD).

When did Prometheus Biosciences IPO?

(RXDX) raised $126 million in an IPO on Friday, March 12th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

What is Prometheus Biosciences' stock symbol?

Prometheus Biosciences trades on the NASDAQ under the ticker symbol "RXDX."

Who are Prometheus Biosciences' major shareholders?

Prometheus Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include RTW Investments LP (6.88%), BlackRock Inc. (5.89%), Fred Alger Management LLC (2.79%), Perceptive Advisors LLC (2.66%), State Street Corp (2.60%) and FMR LLC (2.41%). Insiders that own company stock include Joseph C Papa, Keith W Marshall, Mark C Mckenna, Mark Stenhouse, Perceptive Advisors Llc and Sinai Intellectual Prop Cedars.
View institutional ownership trends
.

How do I buy shares of Prometheus Biosciences?

Shares of RXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prometheus Biosciences' stock price today?

One share of RXDX stock can currently be purchased for approximately $198.60.

How much money does Prometheus Biosciences make?

Prometheus Biosciences (NASDAQ:RXDX) has a market capitalization of $9.50 billion and generates $4.00 million in revenue each year. The biopharmaceutical company earns $-141,750,000.00 in net income (profit) each year or ($3.52) on an earnings per share basis.

Does Prometheus Biosciences have any subsidiaries?
The following companies are subsidiares of Prometheus Biosciences: Prometheus Laboratories Inc..
Read More
How can I contact Prometheus Biosciences?

Prometheus Biosciences' mailing address is 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States. The official website for the company is ignyta.com. The biopharmaceutical company can be reached via phone at 858-422-4300 or via email at nkurdi@prometheusbiosciences.com.

This page (NASDAQ:RXDX) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -